The proconvulsant effect of sildenafil in mice: role of nitric oxide-cGMP pathway

被引:78
作者
Riazi, Kiarash
Roshanpour, Maryam
Rafiei-Tabatabaei, Neda
Homayoun, Houman
Ebrahimi, Farzad
Dehpour, Ahmad Reza
机构
[1] Univ Tehran Med Sci, Dept Pharmacol, Sch Med, Tehran, Iran
[2] Univ Tehran Med Sci, Sch Pharm, Tehran, Iran
关键词
sildenafil; clonic seizure threshold; pentylenetetrazole; bicuculine; nitric oxide; L-NAME; L-arginine; sodium nitroprusside; mice;
D O I
10.1038/sj.bjp.0706680
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Recent evidence indicates that sildenafil may exert some central effects through enhancement of nitric oxide (NO)-mediated effects. NO is known to have modulatory effects on seizure threshold, raising the possibility that sildenafil may alter seizure susceptibility through NO-mediated mechanisms. This study was performed to examine whether sildenafil influences the threshold of clonic and/or generalized tonic seizures through modulation of nitric oxide (NO)-cGMP pathway. 2 The effect of sildenafil (1-40 mg kg(-1)) was investigated on clonic seizures induced by intravenous administration of GABA antagonists pentylenetetrazole (PTZ) and bicuculine and on generalized tonic seizures induced by intraperitoneal administration of high dose PTZ in male Swiss mice. The interaction of sildenafil-induced effects with NO-cGMP pathway was examined using nitric oxide synthase (NOS) inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME), NOS substrate L-arginine, NO donor, sodium nitroprusside (SNP) and guanylyl cyclase inhibitor methylene blue (MB). 3 Sildenafil induced a dose-dependent proconvulsant effect in both models of clonic, but not generalized tonic type of seizures. Pretreatment with either MB or L-NAME inhibited the proconvulsant effect of sildenafil, indicating the mediation of this effect by NO-cGMP pathway. In addition, a subeffective dose of sildenafil induced an additive proconvulsant effect when combined with either L-arginine or SNP. 4 Sildenafil induces a proconvulsant effect on clonic seizure threshold that interacts with both exogenously and endogenously released NO and may be linked to activation of NO-cGMP pathway.
引用
收藏
页码:935 / 943
页数:9
相关论文
共 46 条
  • [1] Preclinical safety profile of sildenafil
    Abbott, D
    Comby, P
    Charuel, C
    Graepel, P
    Hanton, G
    Leblanc, B
    Lodola, A
    Longeart, L
    Paulus, G
    Peters, C
    Stadler, J
    [J]. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2004, 16 (06) : 498 - 504
  • [2] Analysis of the mechanism underlying the peripheral antinociceptive action of sildenafil in the formalin test
    Ambriz-Tututi, M
    Velázquez-Zamora, DA
    Urquiza-Marín, H
    Granados-Soto, V
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 512 (2-3) : 121 - 127
  • [3] Effect of diabetes on the mechanisms of intrathecal antinociception of sildenafil in rats
    Araiza-Saldaña, CI
    Reyes-García, G
    Bermúdez-Ocaña, DY
    Pérez-Severiano, F
    Granados-Soto, V
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 527 (1-3) : 60 - 70
  • [4] Sildenafil increases diclofenac antinociception in the formalin test
    Asomoza-Espinosa, R
    Alonso-López, R
    Mixcoatl-Zecuatl, T
    Aguirre-Bañuelos, P
    Torres-López, JE
    Granados-Soto, V
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 418 (03) : 195 - 200
  • [5] Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice
    Baratti, CM
    Boccia, MM
    [J]. BEHAVIOURAL PHARMACOLOGY, 1999, 10 (08): : 731 - 737
  • [6] Boolell M, 1996, Int J Impot Res, V8, P47
  • [7] Sildenafil citrate: A therapeutic update
    Boyce, EG
    Umland, EM
    [J]. CLINICAL THERAPEUTICS, 2001, 23 (01) : 2 - 23
  • [8] Blockade of phencyclidine-induced effects by a nitric oxide donor
    Bujas-Bobanovic, M
    Bird, DC
    Robertson, HA
    Dursun, SM
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (05) : 1005 - 1012
  • [9] Use of recreational Viagra among men having sex with men
    Crosby, R
    DiClemente, RJ
    [J]. SEXUALLY TRANSMITTED INFECTIONS, 2004, 80 (06) : 466 - 468
  • [10] DESARRO GB, 1991, FUNDAM CLIN PHARM, V5, P503